Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt

Advanced Drug Delivery Reviews

Volumn 61, Issue 13, 2009, Pages 1131-1148

  Duncan, Ruth ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer; HPMA copolymers; Nanomedicines; Phase I II; Polymer therapeutics

Indexed keywords

CANCER; HPMA COPOLYMERS; NANOMEDICINES; PHASE I/II; POLYMER THERAPEUTICS;

CHEMOTHERAPY; COPOLYMERIZATION; COPOLYMERS; DRUG DELIVERY; LIGANDS; MEDICAL NANOTECHNOLOGY; PLASTIC PRODUCTS; POLYMERS; TUMORS;

FUNCTIONAL POLYMERS;

ANTHRACYCLINE; ANTHRACYCLINE N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; ANTINEOPLASTIC AGENT; AP 5280; AP 5346; CAMPTOTHECIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; CARBOPLATIN; CARBOPLATIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; DOXORUBICIN; DOXORUBICIN GALACTOSE N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; DOXORUBICIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; FCE 28068; FCE 28069; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; OPAXIO; OXALIPLATIN; OXALIPLATIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PACLITAXEL N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PACLITAXEL POLIGLUMEX; PNU 166148; PNU 166945; POLYSORBATE 80; PROLINDAC; UNCLASSIFIED DRUG;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLADDER DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CYSTITIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DYSURIA; FATIGUE; FLU LIKE SYNDROME; HEAD AND NECK TUMOR; HEMATURIA; HUMAN; INJECTION SITE PAIN; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR WEIGHT; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NANOMEDICINE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TOXICITY TESTING; VOMITING;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; NANOMEDICINE;

EID: 70349987594     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.05.007     Document Type: Review

References (105)

1. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 51 (1975) 135-153
2. Debruyne F.M., Denis L., Lunglmayer G., Mahler C., Newling D.W., Richards B., Robinson M.R., Smith P.H., Weil E.H., and Whelan P. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J. Urol. 140 (1988) 775-777
3. Sipos E.P., and Brem H. New delivery systems for brain tumor therapy. Neurol. Clin. 13 (1995) 813-825
4. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
5. Danauser-Reidl S., Hausmann E., Schick H., Bender R., Dietzfelbinger H., Rastetter J., and Hanauske A.R. Phase-I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs 11 (1993) 187-195
6. Ochi Y., Shiose Y., Kuga H., and Kumazawa E. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother. Pharmacol. 55 (2005) 323-332
7. Duncan R., and Kopecek J. Soluble synthetic polymers as potential drug carriers. Adv. Polym. Sci. 57 (1984) 51-101
8. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 3 (1992) 175-210
9. Duncan R., and Spreafico F. Polymer conjugates: pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27 (1994) 290-306
10. Duncan R., Dimitrijevic S., and Evagorou E.G. The role of polymer conjugates in the diagnosis and treatment of cancer. S.T.P. Pharma Sci. 6 (1996) 237-263
11. Brocchini S., and Duncan R. Pendent drugs, release from polymers. In: Mathiowitz E. (Ed). Encyclopaedia of Controlled Drug Delivery (1999), John Wiley & Sons, New York 786-816
12. Kopecek J., Kopeckova P., Minko T., and Lu Z.-R. HPMA copolymer-anticancer drug conjugates: design, activity and mechanism of action. Eur. J. Pharm. Biopharm. 50 (2000) 61-81
13. Duncan R. N-(2-Hydroxypropyl)methacrylamide copolymer conjugates. In: Kwon G.S. (Ed). Polymeric Drug Delivery Systems (2005), Marcel Dekker, Inc., New York 1-92
14. Paul A., Vicent M.J., Duncan R., Grillo I., and Heenan R.K. Probing the solution conformation of HPMA copolymer doxorubicin conjugates using small-angle neutron scattering. Biomacromolecules 8 (2007) 1573-1579
15. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
16. European Science Foundation Forward Look on Nanomedicine (2005). http://www.esf.org www.esf.org
17. Duncan R., Seymour L.C.W., Scarlett L., Lloyd J.B., Rejmanova P., and Kopecek J. Fate of N-(2-Hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880 (1986) 62-71
18. Vasey P., Twelves C., Kaye S., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., and Frigerio E. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
19. Kopecek J., and Bazilova H. Poly[N-(hydroxypropyl)methecrylamide]-I. Radical polymerisation and copolymerisation. Eur. Polym. J. 9 (1973) 7-14
20. Flanagan P.A., Duncan R., Rihova B., Subr V., and Kopecek J. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates measured in A/J and B10 mice. J. Bioact. Compat. Polym. 5 (1990) 151-166
21. Kopecek J. Reactive copolymers of N-(2-hydroxypropyl)methacrylamide with N-methacryloylated derivatives of l-leucine and l-phenylalanine. Macromol. Chem. 178 (1977) 2169-2183
22. Pimm M.V., Perkins A.C., Duncan R., and Ulbrich K. Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J. Drug Target. 1 (1993) 125-131
23. 123I-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J. Drug Target. 3 (1996) 375-383
24. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., and Cassidy J. Phase II Studies of Polymer-Doxorubicin (PK1, FCE28068) in the Treatment of Breast, Lung and Colorectal Cancer. J. Clin. Oncol. 34 (2009) 1629-1636
25. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Payner R., Doran J., Young A.M., Burtles S., and Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668-1676
26. Kopecek J. Biodegradation of polymers for biomedical use. In: Benoit H., and Rempp P. (Eds). IUPAC Macromolecules (1982), Pergamon Press, Oxford 305-320
27. Duncan R. Polymer-drug conjugates. In: Budman D., Calvert H., and Rowinsky E. (Eds). Handbook of Anticancer Drug Development (2003), Lippincott, Williams & Wilkins, Philadelphia 239-260
28. Matsumura Y., and Maeda H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 6 (1986) 6387-6392
29. Wedge S.R., Duncan R., and Kopeckova P. Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl) methacrylamide copolymers following intravenous administration in the rat. Brit. J. Cancer 63 (1991) 546-549
30. Seib F.P., Jones A.T., and Duncan R. Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation of B16F10 cells and use to study the intracellular fate of HPMA copolymer-doxorubicin. J. Drug Target. 14 (2006) 375-390
31. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., and van-Hoof F. Lysosomotropic agents. Biochem. Pharmacol. 23 (1974) 2495-2531
32. Cassidy J., Duncan R., Morrison G.J., Strohalm J., Plocova D., Kopecek J., and Kaye S.B. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 38 (1989) 875-879
33. Seymour L.W., Ulbrich K., Styger P.S., Brereton M., Subr V., Strohalm J., and Duncan R. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Brit. J. Cancer 70 (1994) 636-641
34. Sat Y.N., Burger A.M., Fiebig H.H., Sausville E.A., and Duncan R. Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer-doxorubicin (PK1) in human tumour xenografts. Proc. Am. Assoc. Cancer Res. 90 (1999) 41
35. Duncan R., Cable H.C., Lloyd J.B., Rejmanova P., and Kopecek J. Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chains in poly [N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184 (1984) 1997-2008
36. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H.M., Schot M., Mandjes I.A.M., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., and Beijnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 12 (2001) 315-323
37. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., Ulbrich K., Strohalm J., Subr V., Spreafico F., Grandi M., Ripamonti M., Farao M., and Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release 19 (1992) 331-346
38. Chipman S.D., Oldham F.B., Pezzoni G., and Singer J.W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomed. 1 (2006) 375-383
39. Li C., and Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 60 (2008) 886-898
40. Paz-Ares L., Ross H., O'Brien M., Riviere A., Gatzemeier U., Von Pawel J., Kaukel E., Freitag L., Digel W., Bischoff H., García-Campelo R., Iannotti N., Reiterer P., Bover I., Prendiville J., Eisenfeld A.J., Oldham F.B., Bandstra B., Singer J.W., and Bonomi P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 20 (2008) 1608-1613
41. Minko T., Kopeckova P., and Kopecek J. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin. Macromol. Symp. 172 (2001) 35-37
42. Kovar L., Ulbrich K., Kovar M., Strohalm J., Stastny M., Etrych T., and Rihova B. The effect of HPMA copolymer-bound doxorubicin conjugates on the expression of genes involved in apoptosis signaling. J. Control. Release 91 (2003) 247-248
43. Ríhová B., Strohalm J., Hovorka O., Subr V., Etrych T., Chytil P., Pola R., Plocová D., Boucek J., and Ulbrich K. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences. J Control. Release 127 (2008) 110-120
44. Malugin A., Kopeckova P., and Kopecek J. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian cancer cells by a Fas-independent pathway. Mol. Pharmacol. 1 (2004) 174-182
45. Ríhová B., Kovár L., Kovár M., and Hovorka O. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics. Trends Biotechnol. 27 (2009) 11-17
46. Rihova B., Strohalm J., Kubackova K., Jelinkova M., Hovorka O., Kovar M., Plocova D., Sirova M., St'astny M., Rozprimova L., and Ulbrich K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Control. Release 78 (2002) 97-114
47. Rihova B., Strohalm J., Kubácková K., Jelínková M., Rozprimová L., Sírová M., Plocová D., Mrkvan T., Kovár M., Pokorná J., Etrych T., and Ulbrich K. Drug-HPMA-HuIg conjugates effective against human solid cancer. Adv. Exp. Med. Biol. 519 (2003) 125-143
48. 125I-labelled poly(vinylpyrrolidone) on its pinocytosis by rat visceral yolk sacs and rat peritoneal macrophages. Biochem. J. 196 (1980) 49-55
49. Seymour L.W., Duncan R., Strohalm J., and Kopecek J. Effect of molecular weight (Mω) of N-(2-hydroxypropyl)methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mater. Res. 21 (1987) 1341-1358
50. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., and Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31 (1995) 766-770
51. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., and Maeda H. Early phase tumour accumulation of macromolecules: a great difference in clearance rate between tumour and normal tissues. Jpn. J. Cancer Res. 89 (1998) 307-314
52. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., and Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10 (2004) 225-261
53. Rejmanova P., Kopecek J., Duncan R., and Lloyd J.B. Stability in plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials 6 (1985) 45-48
54. Schoemaker N.E., van Kesteren C., Rosing H., Jansen S., Swart M., Lieverst J., Fraier D., Breda M., Pellizzoni C., Spinelli R., Grazia P.M., Beijnen J.H., Schellens J.H., and Bokkel Huinink W.W. A phase I clinical and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Br. J. Cancer 87 (2002) 608-614
55. Bissett D., Cassidy J., de Bono J.S., Muirhead F., Main M., Robson L., Fraier D., Magne M.L., Pellizzoni C., Porro M.G., Spinelli R., Speed W., and Twelves C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 91 (2004) 50-55
56. Wachters F.M., Groen H.J.M., Maring J.G., Gietema J.A., Porro M., Dumez H., de Vries E.G.E., and van Oosterom A.T. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br. J. Cancer 90 (2004) 2261-2267
57. Gianasi E., Wasil M., Evagorou E.G., Keddle A., Wilson G., and Duncan R. HPMA copolymer platinates as novel antitumor agents: in-vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35 (1999) 994-1002
58. Gianasi E., Buckley R.G., Latigo J., Wasil M., and Duncan R. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Target. 10 (2002) 549-556
59. Rice J.R., Gerberich J.L., Nowotnik D.P., and Howell S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer Res. 12 (2006) 2248-2254
60. Duncan R., Cable H.C., Rejmanova P., Kopecek J., and Lloyd J.B. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys. Acta 799 (1984) 1-8
61. Duncan R., Kopecek J., Rejmanova P., and Lloyd J.B. Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta 755 (1983) 518-521
62. Seymour L.W., Ulbrich K., Wedge S.R., Hume I.C., Strohalm J., and Duncan R. N(-2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA, mice. Br. J. Cancer 63 (1991) 859-866
63. Rihova B., and Riha I. Immunological problems of polymer-bound drugs. CRC Crit. Rev. Therapeut. Drug Carrier Syst. 1 (1984) 311-374
64. Rihova B. Biocompatibility of biomaterials: haematocompatibility, immunocompatibility, and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv. Drug Deliv. Rev. 21 (1996) 157-176
65. Fraier D., Frigerio E., Pianezzola E., Strolin Benedetti M., Cassidy J., and Vasey P. A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone in human plasma and urine by reverse phase HPLC with fluorometric detection. J. Pharm. Biomed. Anal. 13 (1995) 625-631
66. Duncan R., Coatsworth J.K., and Burtles S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Human Exp. Toxicol. 17 (1998) 93-104
67. Rihova B., Bilej M., Vetvicka V., Ulbrich K., Strohalm J., Kopecek J., and Duncan R. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, and effect of haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10 (1989) 335-342
68. Yeung T.K., Hopewell J.W., Simmonds R.H., Seymour L.W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., and Ulbrich K. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl) methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29 (1991) 105-111
69. Hopewell J.W., Duncan R., Wilding D., and Chakrabarti D.K. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Human Exp. Toxicol. 20 (2001) 461-470
70. 1H NMR: FCE 28068 and FCE 28069. Magn. Reson. Chem. 35 (1997) 2-8
71. Mendichi R., Rizzo V., Gigli M., and Schieroni A. Molecular characterisation of polymeric antitumour drug carriers by size exclusion chromatography and universal calibration. J. Liq. Chromatogr. Relat. Technol. 19 (1996) 1591-1605
72. Mendichi R., Rizzo V., Gigli M., Razzano G., Angelucci F., and Schieroni A. Molar mass distribution of a polymer-drug conjugate containing the antitumor drug paclitaxel by size exclusion chromatography and universal calibration. J. Liq. Chromatogr. Relat. Technol. 21 (1998) 1295-1309
73. Mendichi R., Rizzo V., Gigli M., and Schieroni A.G. Dilute-solution properties of a polymeric antitumor drug carrier by size-exclusion chromatography, viscometry, and light scattering. J. Appl. Polym. Sci. 70 (1998) 329-338
74. Configliacchi E., Razzano G., Rizzo V., and Vigevani A. HPLC methods for the determination of bound and free doxorubicin and of bound and free galactosamine in methacrylamide polymer-drug conjugates. J. Pharm. Biomed. Anal. 15 (1996) 123-129
75. Bouma M., Nuijen B., Stewart D.R., Shannon K.F., St John J.V., Rice J.R., Harms R., Jansen B.A., van Zutphen S., Reedijk J., Bult A., and Beijnen J.H. Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280. J. Pharm. Sci. Technol. 57 (2003) 198-207
76. Sood P., Thurmond II K.B., Jacob J.E., Waller L.K., Silva G.O., Stewart D.R., and Nowotnik D.P. Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug. Chem. 17 (2006) 1270-1279
77. Tibben M.M., Rademaker-Lakhai J.M., Rice J.R., Stewart D.R., Schellens J.H., and Beijnen J.H. Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Anal. Bioanal. Chem. 373 (2002) 233-236
78. Cavallo R., Adami M., Magrini R., and Colombo G. PK1/PK2 lyophilised formulations. HPMA doxorubicin conjugates with potentially improved antitumour activity. Proc. 1st World Meeting APGI/APV, Budapest (1995) 843
79. Bouma M., Nuijen B., Stewart D.R., Rice J.R., Jansen B.A., Reedijk J., Bult A., and Beijnen J.H. Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential. Anticancer Drugs 13 (2002) 915-924
80. Bouma M., Nuijen B., Harms R., Rice J.R., Nowotnik D.P., Stewart D.R., Jansen B.A., van Zutphen S., Reedijk J., van Steenbergen M.J., Talsma H., Bult A., and Beijnen J.H. Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280. Drug Dev. Ind. Pharm. 29 (2003) 981-995
81. Caiolfa V.R., Zamal M., Fiorini A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., Farao M., Pesenti E., Gigli M., Angelucci F., and Suarato A. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Control. Release 65 (2000) 105-119
82. Zamai M., VandeVen M., Farao M., Gratton E., Ghiglieri A., Castelli M.G., Fontana E., D'Argy R., Fiorino A., Pesenti E., Suarato A., and Caiolfa V.R. Camptothecin poly[N-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Mol. Cancer Ther. 2 (2003) 29-40
83. Chirico G., Collini M., Olivini F., Zamai M., Frigerio E., and Caiolfa V.R. Aggregation properties of a HPMA-camptothecin copolymer in isotonic solutions. Biophys. Chem. 110 (2004) 281-295
84. de Bono J.S., Bissett D., Twelves C., Main M., Muirhead F., Robson L., Fraier D., Magne M., Porro M.G., Speed W., and Cassidy J. Phase I pharmacokinetic study of MAG-CPT (PNU 166148) a polymeric derivative of camptothecin. Proc. Am. Soc. Clin. Oncol. (2000) 771
85. Schoemaker N.E., Frigerio E., Fraier D., Schellens J.H.M., Rosing H., Jansen S., and Beijnen J. High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecicn derivative (MAG-camptothecin) and free camptothecin in human plasma. J. Chromatogr. 763 (2001) 173-183
86. Sarapa N., Britto M.R., Speed W., Jannuzzo M.G., Breda M., James C., Porro M.G., Rocchetti M., and Nygren P. Targeted delivery and preferential uptake in solid cancer of MAG-CPT, a polymer bound prodrug of camptothecin - a trial in patients undergoing surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. 52 (2003) 424-430
87. Lin X., Zhang Q., Rice J.R., Stewart D.R., Nowotnik D.P., and Howell S.B. Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur. J. Cancer 40 (2004) 291-297
88. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., De Boer R.F., Pluim D., Beijnen J.H., Schellens J.H., and Droz J.P. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 15 (2004) 3386-3395
89. Rice J.R., Gerberich J.L., Nowotnik D.P., and Howell S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 12 (2006) 2248-2254
90. Campone M., Rademaker-Lakhai J.M., Bennouna J., Howell S.B., Nowotnik D.P., Beijnen J.H., and Schellens J.H. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother. Pharmacol. 60 (2007) 523-533
91. Kasuya Y., Lu Z.R., Kopecková P., Tabibi S.E., and Kopecek J. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates, influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm. Res. 19 (2002) 115-123
92. Varticovski L., Lu Z.R., Mitchell K., de Aos I., and Kopecek J. Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. J. Control. Release 74 (2001) 275-281
93. Vicent M.J., Manzanaro S., de la Fuente J.A., and Duncan R. HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics. J. Drug Target. 12 (2004) 503-515
94. Vicent M.J., Greco F., Nicholson R.I., and Duncan R. Polymer-drug conjugates as a novel combination therapy for the treatment of hormone-dependent cancers. Angew. Chem. Int. Ed. 44 (2005) 2-6
95. Greco F., Vicent M.J., Penning N.A., Nicolson R.I., and Duncan R. HPMA-copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J. Drug Target. 13 (2005) 459-470
96. Greco F., Vicent M.J., Gee S., Jones A.T., Gee J., Nicholson R.I., and Duncan R. The mechanism of enhanced cytotoxicity of HPMA-copolymer-Dox-AGM in breast cancer cells. J. Control. Release 117 (2007) 28-39
97. T. Lammers, V. Subr, K. Ulbrich, P. Peschke, P.E. Huber, W.E. Hennink, G. Storm, Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers, Biomaterials 30 (20) (2009) 3466-3475.
98. Lammers T., Subr V., Peschke P., Kühnlein R., Hennink W.E., Ulbrich K., Kiessling F., Heilmann M., Debus J., Huber P.E., and Storm G. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer 16 (2008) 900-910
99. Chytil P., Etrych T., Konák C., Sírová M., Mrkvan T., Ríhová, and Ulbrich K. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. J. Control. Release 115 (2006) 26-36
100. Ali M., and Brocchini S. Synthetic approaches to uniform polymers. Adv. Drug Deliv. Rev. 30 (2006) 1671-1687
101. Gaspar R. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. Nanomedicine 2 (2007) 143-147
102. Shaffer S.A., Baker-Lee C., Kennedy J., Lai M.S., de Vries P., Buhler K., and Singer J.W. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother. Pharmacol. 59 (2007) 537-548
103. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 371-716
104. Walker I., and Newell H. Do molecularly targeted agents in oncology have reduced attrition rates?. Nat. Rev. Drug Discov. 8 (2009) 15-16
105. Greco F., and Vicent M.J. Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61 (2009) 1203-1213